Pyoderma gangrenosum associated with chronic refractory pouchitis: A case successfully treated with infliximab

4Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Pouchitis-associated pyoderma gangrenosum (PG) is rare, with only a few cases reported in the literature. Here we report a rare case of chronic refractory pouchitis-associated PG successfully treated with infliximab (IFX). A 43-year-old Caucasian male, with a past medical history of chronic refractory pouchitis after proctocolectomy and ileal pouch-anal anastomosis for severe ulcerative colitis, developed PG on his right lower leg. This subsided after treatment with intravenous IFX at a dose of 5 mg/kg at weeks 0, 2, 6 and then every 8 weeks. Pouchitis-associated PG is rare. Clinicians should be aware of the risk of PG in patients who suffer from pouchitis and develop rapidly extensive painful ulcers. Furthermore, the therapeutic choice should take into consideration the effectiveness of IFX on the inflammatory background, which sustains both intestinal and skin disease in these types of patients.

Cite

CITATION STYLE

APA

Koumaki, D., Orfanoudaki, E., Machaira, A., Lagoudaki, E., Krasagakis, K., & Koutroubakis, I. E. (2020). Pyoderma gangrenosum associated with chronic refractory pouchitis: A case successfully treated with infliximab. Annals of Gastroenterology, 33(4), 433–435. https://doi.org/10.20524/aog.2020.0500

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free